28314676|t|First and second generation DESs reduce diabetes adverse effect on mortality and re-intervention in multivessel coronary disease: 9- Year analysis
28314676|a|Diabetes portends an increased risk of adverse early and late outcomes in patients undergoing PCI. In this study, we aimed to investigate if the adverse effect of diabetes mellitus (DM) on early and late PCI outcomes is reduced with drug-eluting (DES) compared to bare-metal (BMS) stents. We reviewed the Mount Sinai Beth Israel Hospital first PCI experience for multivessel coronary artery disease (CAD, 1998-2009). Patients were excluded if they had single-vessel CAD, emergency, no stent, prior bypass graft or myocardial infarction <24h. Diabetes - effect was derived from 9- year all-cause mortality and re-intervention risk-adjusted hazard ratios [AHR (95% confidence intervals)] for DES (N=2679; 48% three-vessel; 39% DM) and BMS (N=2651; 40% three-vessel; 33% DM) and then stratified based on stent (DES / BMS) and vessel disease (two / three). Diabetes - effect on mortality was lower for DES (AHRDM/NoDM =1.41 [1.14-1.74]) versus BMS (AHRDM/NoDM =1.71 [1.50-2.01]), but this was predominantly driven by two-vessel patients. This diabetes effect was similar for first (DES1: AHRDM/NoDM =1.43 [1.14-1.79]) and second (DES2: AHRDM/NoDM =1.53 [0.77-3.07]) generation DES. Re-intervention comparisons were similarly increased by diabetes in all sub-cohorts. Our analysis of a large real-world PCI series indicates that diabetes is associated with worse 9- year mortality irrespective of stent type, albeit this is mitigated to varying degrees with DES, particularly in DES2 and in case of 2-vessel disease. A complementary stent - effect analysis confirmed DES -to- BMS and DES2 -to- DES1 superiority in both diabetics and non-diabetics.
28314676	0	5	First	T081	C0205435
28314676	10	16	second	T081	C0205436
28314676	17	27	generation	T079	C0079411
28314676	28	32	DESs	T074	C1322815
28314676	33	39	reduce	T080	C0392756
28314676	40	48	diabetes	T047	C0011847
28314676	49	63	adverse effect	T046	C0879626
28314676	67	76	mortality	T081	C0205848
28314676	81	96	re-intervention	T061	C0184661
28314676	100	111	multivessel	T023	C0005847
28314676	112	128	coronary disease	T047	C0010054
28314676	133	137	Year	T079	C0439234
28314676	138	146	analysis	T062	C0936012
28314676	147	155	Diabetes	T047	C0011847
28314676	156	164	portends	T169	C0205245
28314676	168	177	increased	T081	C0205217
28314676	178	182	risk	T078	C0035647
28314676	186	193	adverse	T046	C0879626
28314676	194	199	early	T079	C1279919
28314676	204	208	late	T079	C0205087
28314676	209	217	outcomes	T169	C1274040
28314676	221	229	patients	T101	C0030705
28314676	241	244	PCI	T061	C1532338
28314676	254	259	study	T062	C2603343
28314676	273	284	investigate	T169	C1292732
28314676	292	306	adverse effect	T046	C0879626
28314676	310	327	diabetes mellitus	T047	C0011849
28314676	329	331	DM	T047	C0011849
28314676	336	341	early	T079	C1279919
28314676	346	350	late	T079	C0205087
28314676	351	354	PCI	T061	C1532338
28314676	355	363	outcomes	T169	C1274040
28314676	367	374	reduced	T080	C0392756
28314676	380	392	drug-eluting	T074	C1322815
28314676	394	397	DES	T074	C1322815
28314676	411	434	bare-metal (BMS) stents	T074	C2825200
28314676	439	447	reviewed	T078	C1552617
28314676	452	484	Mount Sinai Beth Israel Hospital	T073,T093	C0019994
28314676	485	490	first	T081	C0205435
28314676	491	494	PCI	T061	C1532338
28314676	510	521	multivessel	T023	C0005847
28314676	522	545	coronary artery disease	T047	C0010054
28314676	547	550	CAD	T047	C0010054
28314676	564	572	Patients	T101	C0030705
28314676	578	586	excluded	T052	C2828389
28314676	599	616	single-vessel CAD	T047	C0581374
28314676	618	627	emergency	T078	C1561583
28314676	629	631	no	T033	C1513916
28314676	632	637	stent	T074	C0038257
28314676	639	644	prior	T079	C0332152
28314676	645	657	bypass graft	T061	C0185098
28314676	661	682	myocardial infarction	T047	C0027051
28314676	689	697	Diabetes	T047	C0011847
28314676	700	706	effect	T080	C1280500
28314676	727	731	year	T079	C0439234
28314676	742	751	mortality	T081	C0205848
28314676	756	771	re-intervention	T061	C0184661
28314676	772	799	risk-adjusted hazard ratios	T081	C2985465
28314676	801	804	AHR	T081	C2985465
28314676	810	830	confidence intervals	T081	C0009667
28314676	837	840	DES	T074	C1322815
28314676	854	866	three-vessel	T047	C3272265
28314676	872	874	DM	T047	C0011849
28314676	880	883	BMS	T074	C2825200
28314676	897	909	three-vessel	T047	C3272265
28314676	915	917	DM	T047	C0011849
28314676	948	953	stent	T074	C0038257
28314676	955	958	DES	T074	C1322815
28314676	961	964	BMS	T074	C2825200
28314676	970	984	vessel disease	T047	C0042373
28314676	986	989	two	T047	C0581375
28314676	992	997	three	T047	C3272265
28314676	1000	1008	Diabetes	T047	C0011847
28314676	1011	1017	effect	T080	C1280500
28314676	1021	1030	mortality	T081	C0205848
28314676	1035	1040	lower	T080	C0205556
28314676	1045	1048	DES	T074	C1322815
28314676	1050	1060	AHRDM/NoDM	T081	C2985465
28314676	1087	1090	BMS	T074	C2825200
28314676	1092	1102	AHRDM/NoDM	T081	C2985465
28314676	1136	1149	predominantly	T080	C1542147
28314676	1160	1170	two-vessel	T047	C0581375
28314676	1171	1179	patients	T101	C0030705
28314676	1186	1194	diabetes	T047	C0011847
28314676	1195	1201	effect	T080	C1280500
28314676	1218	1223	first	T081	C0205435
28314676	1225	1229	DES1	T074	C1322815
28314676	1231	1241	AHRDM/NoDM	T081	C2985465
28314676	1265	1271	second	T081	C0205436
28314676	1273	1277	DES2	T074	C1322815
28314676	1279	1289	AHRDM/NoDM	T081	C2985465
28314676	1309	1319	generation	T079	C0079411
28314676	1320	1323	DES	T074	C1322815
28314676	1325	1340	Re-intervention	T061	C0184661
28314676	1341	1352	comparisons	T052	C1707455
28314676	1368	1377	increased	T081	C0205217
28314676	1381	1389	diabetes	T047	C0011847
28314676	1397	1408	sub-cohorts	T098	C0599755
28314676	1414	1422	analysis	T062	C0936012
28314676	1445	1448	PCI	T061	C1532338
28314676	1471	1479	diabetes	T047	C0011847
28314676	1483	1498	associated with	T080	C0332281
28314676	1499	1504	worse	T033	C1457868
28314676	1508	1512	year	T079	C0439234
28314676	1513	1522	mortality	T081	C0205848
28314676	1523	1535	irrespective	T077	C1254372
28314676	1539	1544	stent	T074	C0038257
28314676	1545	1549	type	T080	C0332307
28314676	1600	1603	DES	T074	C1322815
28314676	1621	1625	DES2	T074	C1322815
28314676	1641	1657	2-vessel disease	T047	C0581375
28314676	1661	1674	complementary	T077	C1254372
28314676	1675	1680	stent	T074	C0038257
28314676	1683	1689	effect	T080	C1280500
28314676	1690	1698	analysis	T062	C0936012
28314676	1699	1708	confirmed	T033	C0750484
28314676	1709	1712	DES	T074	C1322815
28314676	1718	1721	BMS	T074	C2825200
28314676	1726	1730	DES2	T074	C1322815
28314676	1736	1740	DES1	T074	C1322815
28314676	1741	1752	superiority	T080	C0205556
28314676	1761	1770	diabetics	T033	C0241863
28314676	1775	1788	non-diabetics	T033	C0243095